Hot Features
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops ... Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.105 | 0.778065950352 | 13.495 | 14.09 | 13.2 | 865947 | 13.57809089 | CS |
| 4 | -1.34 | -8.96921017403 | 14.94 | 15.79 | 13.12 | 1088625 | 14.0838079 | CS |
| 12 | 1.74 | 14.671163575 | 11.86 | 16.12 | 10.25 | 1465450 | 13.63563448 | CS |
| 26 | 0.53 | 4.05508798776 | 13.07 | 16.12 | 9.82 | 1480483 | 12.60853866 | CS |
| 52 | 7.16 | 111.180124224 | 6.44 | 16.12 | 5.41 | 1743383 | 10.4504964 | CS |
| 156 | 11 | 423.076923077 | 2.6 | 16.12 | 0.97 | 1108997 | 7.63979803 | CS |
| 260 | 11.11 | 446.184738956 | 2.49 | 16.12 | 0.46 | 863650 | 6.36890616 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.